Sellas Life Sciences reported that its vaccine, GPS, extended survival for acute myeloid leukemia patients in a 126-patient trial. The drug cut death risk by 41% compared to standard care. CEO Angelos Stergiou said, "delivering longer life without adding systemic toxicity would be nothing short of transformative." Shares jumped significantly.

The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukemia (AML), who were in remission after cancer therapy ​but were unable to receive a bone marrow or stem-cell transplant.

Sign up here.

AML is ​an aggressive cancer of the blood and bone marrow, and patients ⁠whose disease returns after treatment often face limited care options.

In the 126-patient study, GPS ​cut the risk of death by 41% compared to best available treatment, Sellas said. ​Patients treated with the vaccine lived for a median of 24 months, versus 14.7 months for those in the control group.

The vaccine works by training the body's immune system to find and ​attack leftover leukemia cells that carry a protein called WT1.

For fragile patients "already battered ​by prior lines of intensive chemotherapy, delivering longer life without adding systemic toxicity would be nothing ‌short of ⁠transformative," CEO Angelos Stergiou said on a conference call.

According to the American Cancer Society, about 22,720 people will be diagnosed with AML and about 11,500 are expected to die from the disease in 2026. AML accounts for 1 out of 3 ​leukemia in adults.

Sellas shares ​jumped more than ⁠threefold to $22.93. If gains hold, the company would add roughly $3.1 billion to its market value.

The trial result was "incredibly clinically meaningful", said ​Alliance Global Partners analyst James Molloy. "We believe GPS should receive ​an expedited ⁠approval in 2027 as a monotherapy... and that it could see significant off-label usage earlier in the treatment paradigm as well."

Sellas plans to meet with the US FDA to ⁠discuss an ​accelerated filing strategy, aiming to submit an approval ​application in the first half of 2027.

The New York-based company said the vaccine was generally well tolerated and ​raised no new safety concerns.

Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar